Chronic myeloid leukemia (CML), characterized by the presence of the BCR::ABL1 fusion gene, has undergone a transformative shift with the introduction of tyrosine kinase inhibitors (TKIs). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.